EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand‐1 (PD‐L1) expression in surgically resected non‐small cell lung cancer

Naoko Shigeta iD, Shuji Murakami iD, Tomoyuki Yokose, Tetsuya Isaka iD, Kanako Shinada iD, Takuya Nagashima, Hiroyuki Adachi, Shunsuke Shigefuku, Kotaro Murakami, Jun Miura, Noritake Kikunishi, Kozue Watabe und 2 weitere

Thoracic Cancer · 2024

DOI: 10.1111/1759-7714.15319 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Naoko Shigeta und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, B7-H1 Antigen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Atezolizumab, one of the immune checkpoint inhibitors, has been approved as an adjuvant treatment following resection and platinum‐based chemotherapy in patients with stage II–IIIA non‐small cell lung cancer with 1% or more programmed death ligand‐1 (PD‐L1) expression. The Food and Drug Administration (FDA) has approved SP263 as a companion diagnostic assay for adjuvant treatment with atezolizumab; however, in clinical practice, the 22C3 assay is most commonly used for advanced non‐small cell lung cancer. Therefore, our study aimed to compare two PD‐L1 assays, SP263 and 22C3, to evaluate whether 22C3 could replace SP263 when deciding whether to administer adjuvant atezolizumab.

Methods

We retrospectively and prospectively analyzed 98 patients who underwent surgical resection at Kanagawa Cancer Center (Japan). An immunohistochemistry assay was performed for all the cases with both SP263 and 22C3. We statistically analyzed the concordance of PD‐L1 expression between SP263 and 22C3 assays.

Results

The concordance between the two assays using Cohen's kappa was κ = 0.670 (95% CI: 0.522–0.818) at the 1% cutoff and κ = 0.796 (95% CI: 0.639–0.954) at the 50% cutoff. The Spearman correlation coefficient of 0.874 ( p < 0.01) indicated high concordance. PD‐L1 expression with 22C3 resulted slightly higher than that with SP263.

Conclusions

This study showed a high concordance of PD‐L1 expression with the SP263 and 22C3 assays. Further studies examining the therapeutic effects of adjuvant atezolizumab are required.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsB7-H1 AntigenHumansMaleFemaleAgedMiddle AgedRetrospective StudiesAged, 80 and overProspective StudiesAdultBiomarkers, TumorAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

PD‐L1 immunohistochemistry assayimmune checkpoint inhibitors (ICIs)non‐small cell lung cancer (NSCLC)programmed death ligand‐1

Substanzen

B7-H1 AntigenCD274 protein, humanatezolizumabBiomarkers, TumorAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Japan.
  • Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Japan.
  • Department of Pathology, Kanagawa Cancer Center, Yokohama, Japan.

ORCID-Profile: Naoko Shigeta, Shuji Murakami, Tetsuya Isaka, Kanako Shinada, Haruhiro Saito

Zitieren

APA

Shigeta, N., Murakami, S., Yokose, T., Isaka, T., Shinada, K., Nagashima, T., Adachi, H., Shigefuku, S., Murakami, K., Miura, J., Kikunishi, N., Watabe, K., Saito, H., & Ito, H. (2024). Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand‐1 (PD‐L1) expression in surgically resected non‐small cell lung cancer. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15319

Vancouver

Shigeta N, Murakami S, Yokose T, Isaka T, Shinada K, Nagashima T, et al. Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand‐1 (PD‐L1) expression in surgically resected non‐small cell lung cancer. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15319

BibTeX
@article{Shigeta2024,
  author = {Shigeta, Naoko and Murakami, Shuji and Yokose, Tomoyuki and Isaka, Tetsuya and Shinada, Kanako and Nagashima, Takuya and Adachi, Hiroyuki and Shigefuku, Shunsuke and Murakami, Kotaro and Miura, Jun and Kikunishi, Noritake and Watabe, Kozue and Saito, Haruhiro and Ito, Hiroyuki},
  title = {Comparison of SP263 and 22C3 pharmDx assays to test programmed death ligand‐1 (PD‐L1) expression in surgically resected non‐small cell lung cancer},
  journal = {Thoracic Cancer},
  year = {2024},
  doi = {10.1111/1759-7714.15319}
}
Kostenlos starten →